SCHEMBL24348566

SCHEMBL24348566

Cc1nc2[nH]ncc2c(I)c1F

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR2C P28335 5/20 0.37
▸ HTR2A P28223 4/20 0.36
▸ PLK4 O00444 3/20 0.33
▸ PAK4 O96013 2/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ ACHE P22303 1/20 0.33
▸ PDPK1 O15530 1/20 0.33
▸ SGK1 O00141 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ ROCK2 O75116 2/20 0.32
▸ CHEK1 O14757 1/20 0.32
▸ AURKA O14965 1/20 0.32
▸ RET P07949 1/20 0.32
▸ PI4KA P42356 1/20 0.32
▸ XDH P47989 1/20 0.32
▸ LRRK2 Q5S007 1/20 0.32
▸ PI4K2B Q8TCG2 1/20 0.32
▸ PI4K2A Q9BTU6 1/20 0.32
▸ PI4KB Q9UBF8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30406140 1.00 HTR2C (0.37) HTR2CHTR2APLK4PAK4SMN1; SMN2
SCHEMBL24348512 0.81 HTR2C (0.39) HTR2CHTR2APLK4PAK4SMN1; SMN2
SCHEMBL24348564 0.79 PLK4 (0.39) HTR2CHTR2APLK4PAK4SMN1; SMN2
SCHEMBL24349703 0.79 ACHE (0.44) HTR2CHTR2APLK4PAK4SMN1; SMN2
SCHEMBL26719826 0.76 HTR2C (0.35) HTR2CHTR2APLK4PAK4SMN1; SMN2
SCHEMBL29478852 0.68 PDPK1 (0.43) SMN1; SMN2ALDH1A1PDPK1CHEK1AURKA
SCHEMBL2675945 0.68 PDPK1 (0.43) SMN1; SMN2ALDH1A1PDPK1CHEK1AURKA
SCHEMBL24348563 0.68 ALDH1A1 (0.39) HTR2CPLK4PAK4SMN1; SMN2ALDH1A1
SCHEMBL23858513 0.68 CCNT1 (0.42) SMN1; SMN2ALDH1A1PDPK1HTTCHEK1
SCHEMBL2638970 0.67 FGFR1 (0.35) HTR2CHTR2APLK4PAK4SGK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230339970-A1 CASEIN KINASE 1 DELTA MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2023-10-26 — — US disclosed
EP-4214214-A1 CASEIN KINASE 1 DELTA MODULATORS JANSSEN Pharmaceutica NV (BE) 2023-07-26 — — EP disclosed
CN-116171280-A Casein kinase 1 delta modulators 詹森药业有限公司 2023-05-26 — — CN disclosed
WO-2022058920-A1 CASEIN KINASE 1 DELTA MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2022-03-24 — — WO disclosed
WO-2022058920-A1 CASEIN KINASE 1 DELTA MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2022-03-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339970-A1 CASEIN KINASE 1 DELTA MODULATORS CSNK1D, CSNK1A1, CSNK1G1 HTR2C 1330/4885HTR2A 1343/4885PLK4 556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback